Drug intelligence / Profile preview

TXP1-CC20

Development stage: Preclinical
Lead developer: Ossianix
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

TXP1-CC20 is a preclinical-stage therapeutic candidate being developed by Ossianix for the treatment of Multiple Sclerosis. The drug is part of the TXP1 platform, which utilizes VNAR (Variable New Antigen Receptor) single-domain antibodies derived from cartilaginous fish. TXP1-CC20 consists of a VNAR antibody targeting the CC20 antigen, fused to a brain shuttle component that binds to the Transferrin receptor 1 (TfR1). This shuttle mechanism facilitates the transport of the antibody across the blood-brain barrier (BBB) via receptor-mediated transcytosis, allowing for enhanced CNS delivery and target engagement. This approach is designed to overcome the limitations of conventional antibodies in treating neuroinflammatory diseases by enabling therapeutic concentrations to reach the central nervous system.

Other names: TXP1-CC20-Ossianix-CC20-TfR1-VNAR antibody-brain shuttle-Multiple SclerosisTXP-1-CC20-Ossianix-CC20-TfR1-VNAR antibody-brain shuttle-Multiple SclerosisTXP 1-CC20-Ossianix-CC20-TfR1-VNAR antibody-brain shuttle-Multiple Sclerosis

Targets

TFRC (Transferrin Receptor)DNA

Beyond the preview

Go deeper on TXP1-CC20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXP1-CC20.

Explore the full profile